抑制T细胞增殖的抗CD45单克隆抗体的建立

目的寻找能调节T细胞功能的相关分子,进行与T细胞介导的自身免疫性疾病相关的研究。方法从BALB/c小鼠骨髓中收集树突状细胞,免疫Wistar大鼠,进行细胞融合,建立杂交瘤细胞系。筛选得到很多株能调节T细胞功能的杂交瘤细胞系,对其中一株最能抑制T细胞增殖的杂交瘤细胞系进行了进一步的深入研究。结果显示其目标分子是CD45,同时增殖实验结果显示该抗体能显著抑制T细胞增殖反应。结论抗CD45单克隆抗体能有效抑制T细胞增殖,有望将本抗体用于T细胞介导的自身免疫性疾病的相关预防及治疗中。     

分泌抗北京鸭免疫球蛋白单克隆抗体的淋巴细胞杂交瘤CBH-2(简报)

淋巴细胞杂交瘤技术作为一种新的生物工程技术,已在生物学和医学领域内得到广泛的应用。我们继建立产生抗北京鸭红细胞单克隆抗体的杂交瘤细胞系CBH-1后,又建立了一株产生抗北京鸭免疫球蛋白(I_g)单克隆抗体的杂交瘤细胞系,命名为CBH-2。这种杂交瘤细胞经体外培养,能稳定地分泌抗北京鸭I_g的单克隆抗体。此单克隆抗体在以北京鸭抗体进行放射免疫和酶标等测定时,可用作第二抗体。现将主要结果简报于下。北京鸭I_g抗原的制备及免疫:从北京鸭颈动脉采血,分离血清,用50%和33%硫酸铵沉淀法提取二次。每只Balb/cJ小鼠腹腔免疫剂量为0.3毫克,共免疫三     

一种抗AIV共有独特型抗体具有AIV血凝素分子的内影象

用纯化的鸡抗禽流感病毒(AIV)IgG作免疫原,通过单克隆抗体技术制备出1株分泌针对鸡抗AIV和兔抗AIV共有独特型抗体的杂交瘤细胞.竞争抑制试验、特异性检验和诱导产生血凝抑制抗体的功能实验证明,此抗体具有AIV血凝素分子的内影象.     

一种抗AIV共有独特型抗体具有AIV血凝素分子的内影象

用纯化的鸡抗禽流感病毒(AIV)IgG作免疫原,通过单克隆抗体技术制备出1株分泌针对鸡抗AIV和兔抗AIV共有独特型抗体的杂交瘤细胞。竞争抑制试验、特异性检验和诱导产生血凝抑制抗体的功能实验证明,此抗体具有AIV血凝素分子的内影象。     

高亲和力抗有机磷杀虫剂单克隆抗体的制备与鉴定

制备抗有机磷杀虫剂单克隆抗体。采用人工合成带有特殊功能基团的半抗原,将其与载体蛋白偶联,以半抗原偶联物为免疫原,免疫BALBc小鼠,取免疫小鼠的脾细胞与小鼠骨髓瘤细胞融合,HAT选择、有限稀释法克隆化,建立分泌抗机磷杀虫剂单克隆抗体的杂交瘤细胞系。ELISA间接法和ELISA竞争抑制法检测抗体滴度,非竞争抑制法检测抗体亲和常数。结果获得9株分泌抗机磷杀虫剂单克隆抗体的杂交瘤细胞系,其中7株为型特异性,2株为组特异性;Ig亚型均为IgG1;亲和常数为407×108±043M和127×109±024M。结论为人工人工合成的、含特殊功能基团的半抗原,与载体蛋白偶联后,做免疫原,可用于制备高滴度的抗有机磷杀虫剂单克隆抗体,这种单抗可用于机磷杀虫剂残留物的免疫化学检测 。     

一株新型抗46 ku-细胞角蛋白的单特异性单克隆抗体

利用杂交瘤技术制备了一株单克隆抗体 T2-2,对其生化性质的研究及其与抗细胞角蛋白多克隆抗体完全重合的定位表明,该抗体特异性识别一种分子质量为 46 ku 的角蛋白. 对 68 例正常组织和 65 例肿瘤组织的免疫组化结果显示,单克隆抗体 T2-2 具有上皮细胞特异性. 与其他多数抗细胞角蛋白抗体常与一种以上细胞角蛋白多肽表现出交叉反应不同的是,该抗体只识别 46 ku 细胞角蛋白多肽上的某一单特异性表位. 另外,单克隆抗体 T2-2 适用于多种免疫实验技术,包括 ELISA、免疫组化、细胞免疫荧光及蛋白质印迹等,而且适用于多种固定剂. 以上结果表明,单克隆抗体 T2-2 将成为细胞角蛋白功能研究和肿瘤诊断的有力工具.     

产生抗登革热Ⅰ型病毒单克隆抗体杂交瘤细胞株的建立

用登革热Ⅰ型病毒(夏威夷株)兔疫的小白鼠脾细胞与小鼠骨髓瘤细胞融合,获得7个产生抗登革热Ⅰ型病毒单克隆抗体的杂交瘤细胞系,这些杂交瘤细胞上清液及小鼠腹水抗体均用间接兔疫荧光法检测,其中3个杂交瘤细胞系产生的抗体对登革热Ⅰ型病毒具有型特异性。     

抗甲型肝炎病毒单克隆抗体的研究

我们于1984年开展研究抗甲型肝炎病毒(HBV)的单克隆抗体(McAb),得到了3株能连续传代,稳定分泌抗-HAAg的杂交瘤细胞系,抗体在组织培养上清液中的ELISA滴度为1:800～1:1600,腹水为1:10,000—1:100,000。 用ELISA方法检测三株杂交瘤细胞分泌的抗体与经免疫粘附血凝(IAHA),免疫电镜(IEM)证实的5份甲肝抗原和Abbott公司的甲肝抗原均产生特异性反应。但不与正常人     

抗乙型肝炎病毒e抗原和核心抗原双特异性单克隆抗体的建立与应用

用基因工程技术在大肠杆菌中高效表达的乙型肝炎病毒核心抗原(内含高滴度的e抗原)免疫Balb/C小鼠,取免疫小鼠脾细胞与小鼠骨髓瘤细胞(Sp2/0)融合,获得两株分泌高滴度既抗-HBe又抗-HBc的双特异性杂交瘤细胞系。细胞培养上清液中抗体滴度为100～1000以上;免疫腹水中的抗体滴度为8万至10万以上,均属IgG2a亚类。细胞在实验室连续传代二年多,仍保持高效分泌抗体能力。此单克隆抗体与HBeAg或HBcAg的结合可被抗-HBc或抗-HBc阳性血清所抑制,竞争抑制率在85.9％～96.8％之间。用此单克隆抗体与HBe的β型单克隆抗体和抗HBc的α型单克隆抗体配对,可组装成检测HBeAg/抗-HBe和抗-HBc的诊断试剂,具有重要的应用价值。     

CD4+CD25+调节性T细胞与肿瘤免疫

调节性T细胞是一类具有免疫抑制作用,调节自身T细胞功能的T细胞亚群,与维持免疫耐受、抑制自身免疫性疾病有关,CD4＋CD25＋调节性T细胞是其重要组成部分.该文介绍CD4＋CD25＋调节性T细胞在癌症患者免疫系统中的失调现象、机制和以其为靶点的免疫治疗方式.     

Manipulation of CD98 resolves type 1 diabetes in nonobese diabetic mice

The interplay of CD4(+) and CD8(+) T cells targeting autoantigens is responsible for the progression of a number of autoimmune diseases, including type 1 diabetes mellitus (T1D). Understanding the molecular mechanisms that regulate T cell activation is crucial for designing effective therapies for autoimmune diseases. We probed a panel of Abs with T cell-modulating activity and identified a mAb specific for the H chain of CD98 (CD98hc) that was able to suppress T cell proliferation. The anti-CD98hc mAb also inhibited Ag-specific proliferation and the acquisition of effector function by CD4(+) and CD8(+) T cells in vitro and in vivo. Injection of the anti-CD98hc mAb completely prevented the onset of cyclophosphamide-induced diabetes in NOD mice. Treatment of diabetic NOD mice with anti-CD98hc reversed the diabetic state to normal levels, coincident with decreased proliferation of CD4(+) T cells. Furthermore, treatment of diabetic NOD mice with CD98hc small interfering RNA resolved T1D. These data indicate that strategies targeting CD98hc might have clinical application for treating T1D and other T cell-mediated autoimmune diseases.     

Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor

The two pathways to osteoclastogenesis, RANKL-mediated and CD98-mediated osteoclastogenesis, have recently been reported. RANKL, OCIF, and TIMP-3 mRNAs are not found in monocytes freshly isolated or incubated with anti-FRP-1/CD98hc antibody. RANK, TACE, and M-CSF mRNAs can be detected in these cells. Interestingly, the expressed amount of RANK mRNA increases by cultivation of monocytes with anti-CD98hc antibody and maximal expression is observed in osteoclast-like cells. CD98-mediated cell aggregation and multinucleated giant cell formation are blocked by OCIF. OCIF also suppressed the CD98-mediated induction of Sp1 and c-src mRNAs in monocytes. Soluble RANK shows no effect on CD98-mediated cell aggregation and multinucleated giant cell formation. When blood monocytes were incubated with RANKL and M-CSF, c-src and Sp1 mRNAs were first found in blood monocytes incubated with these cytokines for 7 days. On the contrary, c-src mRNA could be detected 3 h after treatment of blood monocytes with anti-CD98hc mAb. LAT-1 mRNA was not found, and the expression levels of Y(+)LAT-1 and Y(+)LAT-2 mRNAs were not changed in monocytes stimulated without or with anti-CD98hc mAb or RANKL and M-CSF. An inhibitory mAb directed against CD98hc, HBJ 127, shows a suppressive effect on RANKL-mediated cell aggregation and cell fusion. Thus, there is cross-talk between these two pathways.     

CD98hc regulates the development of experimental colitis by controlling effector and regulatory CD4 T cells

CD4⁺ T cell activation is controlled by signaling through the T cell receptor in addition to various co-receptors, and is also affected by their interactions with effector and regulatory T cells in the microenvironment. Inflammatory bowel diseases (IBD) are caused by the persistent activation and expansion of auto-aggressive CD4⁺ T cells that attack intestinal epithelial cells. However, the molecular basis for the persistent activation of CD4⁺ T cells in IBD remains unclear. In this study, we investigated how the CD98 heavy chain (CD98hc, Slc3a2) affected the development of colitis in an experimental animal model. Transferring CD98hc-deficient CD4⁺CD25⁻ T cells into Rag2^−/− mice did not cause colitis accompanied by increasing Foxp3⁺ inducible regulatory T cells. By comparison, CD98hc-deficient naturally occurring regulatory T cells (nTregs) had a decreased capability to suppress colitis induced by CD4⁺CD25⁻ T cells, although CD98hc-deficient mice did not have a defect in the development of nTregs. Blocking CD98hc with an anti-CD98 blocking antibody prevented the development of colitis. Our results indicate that CD98hc regulates the expansion of autoimmune CD4⁺ T cells in addition to controlling nTregs functions, which suggests the CD98hc as an important target molecule for establishing strategies for treating colitis.     

CD98hc (SLC3A2) interaction with the integrin beta subunit cytoplasmic domain mediates adhesive signaling

In mammals, beta1 integrin adhesion receptors generate signals that mediate cell spreading, migration, proliferation, and survival. CD98, a heterodimeric transmembrane protein, physically associates with certain integrin beta subunit cytoplasmic domains (tails) via its heavy chain, CD98hc (SLC3A2), and loss of CD98hc impairs integrin signaling. Here we have used the lack of CD98hc interaction with the Drosophila integrin betaPS tail for a homology scanning analysis that implicated the C-terminal 8 residues of beta3 (Thr(755)-Thr(802)) in CD98hc binding. We then identified point mutations in the beta3 C terminus (T755K and T758M) that abolish CD98hc association and a double mutation in the corresponding residues in the betaPS tail (K839T,M842T), which resulted in gain of CD98hc interaction. Furthermore, the loss of function beta3(T755K) mutation or the gain of function beta3/betaPS(K839T,M842T) led to a loss or gain of integrin-mediated cell spreading, respectively. Thus, we have identified critical integrin residues required for CD98hc interaction and in doing so have shown that CD98c interaction with the integrin beta tail is required for its ability to mediate integrin signaling. These studies also provide new insights into how CD98hc may cooperate with other cytoplasmic domain binding proteins to modulate integrin functions and into the evolution of integrin signaling.     

CD98 Heavy Chain Is a Potent Positive Regulator of CD4+ T Cell Proliferation and Interferon-γ Production In Vivo

Upon their recognition of antigens presented by the MHC, T cell proliferation is vital for clonal expansion and the acquisition of effector functions, which are essential for mounting adaptive immune responses. The CD98 heavy chain (CD98hc, Slc3a2) plays a crucial role in the proliferation of both CD4⁺ and CD8⁺ T cells, although it is unclear if CD98hc directly regulates the T cell effector functions that are not linked with T cell proliferation in vivo. Here, we demonstrate that CD98hc is required for both CD4⁺ T cell proliferation and Th1 functional differentiation. T cell-specific deletion of CD98hc did not affect T cell development in the thymus. CD98hc-deficient CD4⁺ T cells proliferated in vivo more slowly as compared with control T cells. C57BL/6 mice lacking CD98hc in their CD4⁺ T cells could not control Leishmania major infections due to lowered IFN-γ production, even with massive CD4⁺ T cell proliferation. CD98hc-deficient CD4⁺ T cells exhibited lower IFN-γ production compared with wild-type T cells, even when comparing IFN-γ expression in cells that underwent the same number of cell divisions. Therefore, these data indicate that CD98hc is required for CD4⁺ T cell expansion and functional Th1 differentiation in vivo, and suggest that CD98hc might be a good target for treating Th1-mediated immune disorders.     

Metabolic activation-related CD147-CD98 complex

Cell surface CD147 protein promotes production of matrix metalloproteinases and hyaluronan, associates with monocarboxylate transporters and integrins, and is involved in reproductive, neural, inflammatory, and tumor functions. Here we combined covalent cross-linking, mass spectrometric protein identification, and co-immunoprecipitation to show selective CD147 association with three major types of transporters (CD98 heavy chain (CD98hc)-L-type amino acid transporter, ASCT2, and monocarboxylate transporters) as well as a regulator of cell proliferation (epithelial cell adhesion molecule). In the assembly of these multicomponent complexes, CD147 and CD98hc play a central organizing role. RNA interference knock-down experiments established a strong connection between CD147 and CD98hc expression and a strong positive association of CD147 (and CD98hc) with cell proliferation. As the CD147-CD98hc complex and proliferation diminished, AMP-activated protein kinase (a cellular "fuel gauge") became activated, indicating a disturbance of cellular energy metabolism. Our data point to a CD147-CD98 cell surface supercomplex that plays a critical role in energy metabolism, likely by coordinating transport of lactate and amino acids. Furthermore we showed how covalent cross-linking, together with mass spectrometry, can be used to identify closely associated transmembrane proteins. This approach should also be applicable to many other types of transmembrane proteins besides those associated with CD98hc and CD147.     

The membrane-spanning domain of CD98 heavy chain promotes alpha(v)beta3 integrin signals in human extravillous trophoblasts

CD98 heavy chain (CD98hc) is expressed highly in developing human placental trophoblast. CD98hc is an amino acid transporter and is thought to function in cell fusion, adhesion, and invasion by interacting with integrins. In invasive extravillous trophoblast, alpha(v)beta(3) integrin is expressed in a temporally and spatially specific manner, which prompted us to investigate the potential role of CD98hc in signal transduction of alpha(v)beta(3) integrin. Immunocytochemistry of extravillous trophoblast derived from human placenta revealed that CD98hc colocalized with alpha(v)beta(3) integrin and with alpha(v)beta(3)-associated cytoplasmic proteins including paxillin, vinculin, and focal adhesion kinase. Coimmunoprecipitation of CD98hc and its mutants revealed that the transmembrane domain of CD98hc is necessary for the association of CD98hc with alpha(v)beta(3) integrin. When CD98hc negative liver cells (FLC4) were stably transfected with CD98hc and the extracellular domain of CD98hc was cross-linked by anti-CD98 antibody, FLC4 cells binding affinity to fibronectin and cell motility increased. The anti-CD98 antibody cross-linking promoted actin stress fiber formation and activation of signal transduction downstream of RhoA GTPase, and elevated the phosphorylation of focal adhesion kinase, paxillin, and protein kinase B. Pretreatment of transfected FLC4 cells with specific inhibitors for alpha(v)beta(3)integrin, phosphatidylinositol 3-kinase, and RhoA diminished these effects caused by anti-CD98 antibody cross-linking. These results suggest that notoriously invasive activity of extravillous trophoblast is mediated by CD98hc, which promotes alpha(v)beta(3) integrin-dependent signals.     

CD98 increases renal epithelial cell proliferation by activating MAPKs

CD98 heavy chain (CD98hc) is a multifunctional transmembrane spanning scaffolding protein whose extracellular domain binds with light chain amino acid transporters (Lats) to form the heterodimeric amino acid transporters (HATs). It also interacts with β1 and β3 integrins by its transmembrane and cytoplasmic domains. This interaction is proposed to be the mechanism whereby CD98 mediates cell survival and growth via currently undefined signaling pathways. In this study, we determined whether the critical function of CD98-dependent amino acid transport also plays a role in cell proliferation and defined the signaling pathways that mediate CD98-dependent proliferation of murine renal inner medullary collecting duct (IMCD) cells. We demonstrate that downregulating CD98hc expression resulted in IMCD cell death. Utilizing overexpression studies of CD98hc mutants that either lacked a cytoplasmic tail or were unable to bind to Lats we showed that CD98 increases serum-dependent cell proliferation by a mechanism that requires the CD98hc cytoplasmic tail. We further demonstrated that CD98-dependent amino acid transport increased renal tubular epithelial cell proliferation by a mechanism that does not require the CD98hc cytoplasmic tail. Both these mechanisms of increased renal tubular epithelial cell proliferation are mediated by Erk and p38 MAPK signaling. Although increased amino transport markedly activated mTor signaling, this pathway did not alter cell proliferation. Thus, these studies demonstrate that in IMCD cells, the cytoplasmic and extracellular domains of CD98hc regulate cell proliferation by distinct mechanisms that are mediated by common MAPK signaling pathways.     

T cell apoptosis and induction of foxp3+ regulatory T cells underlie the therapeutic efficacy of CD4 blockade in experimental autoimmune encephalomyelitis

The pathogenesis of multiple sclerosis requires the participation of effector neuroantigen-specific T cells. Thus, T cell targeting has been proposed as a promising therapeutic strategy. However, the mechanism underlying effective disease prevention following T cell targeting remains incompletely known. We found, using several TCR-transgenic strains, that CD4 blockade is effective in preventing experimental autoimmune encephalopathy and in treating mice after the disease onset. The mechanism does not rely on direct T cell depletion, but the anti-CD4 mAb prevents the proliferation of naive neuroantigen-specific T cells, as well as acquisition of effector Th1 and Th17 phenotypes. Simultaneously, the mAb favors peripheral conversion of Foxp3(+) regulatory T cells. Pre-existing effector cells, or neuroantigen-specific cells that undergo cell division despite the presence of anti-CD4, are committed to apoptosis. Therefore, protection from experimental autoimmune encephalopathy relies on a combination of dominant mechanisms grounded on regulatory T cell induction and recessive mechanisms based on apoptosis of neuropathogenic cells. We anticipate that the same mechanisms may be implicated in other T cell-mediated autoimmune diseases that can be treated or prevented with Abs targeting T cell molecules, such as CD4 or CD3.